Straits Times Index
3,269.27 -32.69 (-0.99%) Nikkei
28,546.98 +727.65 (+2.62%) Hang Seng
20,175.62 +93.19 (+0.46%) FTSE 100
7,500.89 +34.98 (+0.47%) BTC-USD
24,450.10 +362.88 (+1.51%) CMC Crypto 200
574.64 +3.36 (+0.59%)
Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous close | 14.12 |
| Open | 14.14 |
| Bid | 14.25 x 1800 |
| Ask | 14.26 x 2900 |
| Day's range | 14.15 - 14.27 |
| 52-week range | 13.05 - 17.31 |
| Volume | |
| Avg. volume | 2,616,216 |
| Market cap | 44.252B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 30.32 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.80 (5.65%) |
| Ex-dividend date | 29 Sept 2021 |
| 1y target est | N/A |
- Business Wire
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
OSAKA, Japan, July 28, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance.
- Business Wire
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
OSAKA, Japan & CAMBRIDGE, Mass., July 21, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint. Topline data show that HYQVIA reduced relapse of neuromuscular disability and impairment when used as a
- Business Wire
Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
OSAKA, Japan, July 11, 2022--Takeda Pharmaceutical Company Limited ("Takeda") (TOKYO:4502/NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange ("TSE") in accordance with the regulations* for TSE listed companies. The Report can be accessed on Takeda’s website at: https://www.takeda.com/who-we-are/corporate-governance/.
